Bloomberg reported the Trump administration withdrew White House aide Heidi Overton’s bid to run the Food and Drug Administration (FDA), leaving it without a permanent commissioner ahead of a Senate vote.
The withdrawal occurred Tuesday, Nov. 17, before the Senate Health, Education, Labor and Pensions Committee’s 9:45 a.m. ET meeting Wednesday to decide whether her nomination should advance. Axios attributed the decision to White House concerns that it could not secure enough votes in Congress.
Committee Chairman Bill Cassidy, a Louisiana Republican, had said he believed Overton had enough votes to advance through the committee and the full Senate, as EconoTimes previously reported. Cassidy criticized her role in helping shape President Donald Trump’s proposed changes to childhood vaccination policy. Sen. Susan Collins questioned FDA authorization of fruit-flavored vapes, while Sen. Lisa Murkowski raised concerns about the agency’s approach to mifepristone.
Bloomberg put at about 20% the share of U.S. consumer spending covered by FDA-regulated products. Marty Makary resigned as FDA commissioner in May, 13 months after taking office. Attorney Kyle Diamantas, who once led the FDA’s food center, is running the agency on an interim basis; Bloomberg cited sources familiar with staffing plans who expect him to leave by year-end.
Bloomberg reported that whether the administration can put forward another nominee before Democrats assume Senate control in January remains unresolved.

